CLINICAL TRIALS PROFILE FOR IDELVION

All Clinical Trials for IDELVION

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04108260 ↗	The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients	Recruiting	National Taiwan University Hospital	Phase 4	2020-04-21	The pivotal clinical data support prolonged dosing intervals of up to 14 days for routine prophylaxis in hemophilia B patients. The majority of adult and pediatric patients using Idelvion for routine prophylaxis had a median annualized spontaneous bleeding rate (AsBR) of 0.00. The majority (99%) of bleeding episodes were managed successfully with one or two infusions, and 94% of bleeds were controlled with only one infusion regardless of the cause or location. The rationale for this study is to collect the effectiveness and safety data of severe hemophilia B patients treated with Idelvion following institutional standard of care. It is the aim of this study to extend the results of the clinical trial program to a broader hemophilia B population, and to compare with current alternative factor IX treatments in Taiwan.

Clinical Trial Conditions for IDELVION

Condition Name

Condition Name for IDELVION
Intervention	Trials
Hemophilia	1

Condition MeSH

Condition MeSH for IDELVION
Intervention	Trials
Hemophilia B	1
Hemophilia A	1

Clinical Trial Locations for IDELVION

Trials by Country

Trials by Country for IDELVION
Location	Trials
Taiwan	1

Clinical Trial Progress for IDELVION

Clinical Trial Phase

Clinical Trial Phase for IDELVION
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for IDELVION
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for IDELVION

Sponsor Name

Sponsor Name for IDELVION
Sponsor	Trials
National Taiwan University Hospital	1

Sponsor Type

Sponsor Type for IDELVION
Sponsor	Trials
Other	1